Krystal Biotech (NASDAQ:KRYS – Get Free Report) and VectivBio (NASDAQ:VECT – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.
Profitability
This table compares Krystal Biotech and VectivBio’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Krystal Biotech | 30.69% | 11.41% | 10.40% |
VectivBio | N/A | N/A | N/A |
Institutional & Insider Ownership
86.3% of Krystal Biotech shares are held by institutional investors. 13.7% of Krystal Biotech shares are held by company insiders. Comparatively, 9.7% of VectivBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Volatility and Risk
Valuation and Earnings
This table compares Krystal Biotech and VectivBio”s gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Krystal Biotech | $333.45 million | 11.88 | $10.93 million | $4.16 | 32.95 |
VectivBio | $27.34 million | 20.97 | -$93.74 million | N/A | N/A |
Krystal Biotech has higher revenue and earnings than VectivBio.
Analyst Recommendations
This is a breakdown of current ratings for Krystal Biotech and VectivBio, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Krystal Biotech | 0 | 1 | 7 | 1 | 3.00 |
VectivBio | 0 | 0 | 0 | 0 | 0.00 |
Krystal Biotech currently has a consensus target price of $211.13, indicating a potential upside of 54.03%. Given Krystal Biotech’s stronger consensus rating and higher possible upside, equities analysts clearly believe Krystal Biotech is more favorable than VectivBio.
Summary
Krystal Biotech beats VectivBio on 12 of the 13 factors compared between the two stocks.
About Krystal Biotech
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
About VectivBio
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.